Standard BioTools (LAB) Competitors $1.30 -0.02 (-1.52%) Closing price 04:00 PM EasternExtended Trading$1.30 -0.01 (-0.38%) As of 06:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LAB vs. TXG, EYPT, AEHR, ALNT, TRNS, CTKB, SENS, QSI, FEIM, and MASSShould you be buying Standard BioTools stock or one of its competitors? The main competitors of Standard BioTools include 10x Genomics (TXG), Eyepoint Pharmaceuticals (EYPT), Aehr Test Systems (AEHR), Allient (ALNT), Transcat (TRNS), Cytek Biosciences (CTKB), Senseonics (SENS), Quantum-Si (QSI), Frequency Electronics (FEIM), and 908 Devices (MASS). These companies are all part of the "measuring and control equipment" industry. Standard BioTools vs. Its Competitors 10x Genomics Eyepoint Pharmaceuticals Aehr Test Systems Allient Transcat Cytek Biosciences Senseonics Quantum-Si Frequency Electronics 908 Devices 10x Genomics (NASDAQ:TXG) and Standard BioTools (NASDAQ:LAB) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, media sentiment, valuation, earnings, analyst recommendations, profitability and dividends. Does the media prefer TXG or LAB? In the previous week, 10x Genomics had 10 more articles in the media than Standard BioTools. MarketBeat recorded 10 mentions for 10x Genomics and 0 mentions for Standard BioTools. 10x Genomics' average media sentiment score of 0.77 beat Standard BioTools' score of 0.00 indicating that 10x Genomics is being referred to more favorably in the media. Company Overall Sentiment 10x Genomics Positive Standard BioTools Neutral Do insiders and institutionals hold more shares of TXG or LAB? 84.7% of 10x Genomics shares are owned by institutional investors. Comparatively, 53.7% of Standard BioTools shares are owned by institutional investors. 10.0% of 10x Genomics shares are owned by insiders. Comparatively, 23.2% of Standard BioTools shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has preferable valuation and earnings, TXG or LAB? Standard BioTools has lower revenue, but higher earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Standard BioTools, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio10x Genomics$610.78M2.36-$182.63M-$0.70-16.57Standard BioTools$174.43M2.85-$138.88M-$0.32-4.06 Is TXG or LAB more profitable? 10x Genomics has a net margin of -13.13% compared to Standard BioTools' net margin of -69.08%. 10x Genomics' return on equity of -12.88% beat Standard BioTools' return on equity.Company Net Margins Return on Equity Return on Assets 10x Genomics-13.13% -12.88% -10.03% Standard BioTools -69.08%-20.23%-15.32% Which has more risk & volatility, TXG or LAB? 10x Genomics has a beta of 2.05, suggesting that its share price is 105% more volatile than the S&P 500. Comparatively, Standard BioTools has a beta of 1.31, suggesting that its share price is 31% more volatile than the S&P 500. Do analysts rate TXG or LAB? 10x Genomics currently has a consensus price target of $13.65, suggesting a potential upside of 17.71%. Standard BioTools has a consensus price target of $1.55, suggesting a potential upside of 19.23%. Given Standard BioTools' higher possible upside, analysts clearly believe Standard BioTools is more favorable than 10x Genomics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 10x Genomics 2 Sell rating(s) 8 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.25Standard BioTools 1 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.75 Summary10x Genomics beats Standard BioTools on 10 of the 15 factors compared between the two stocks. Get Standard BioTools News Delivered to You Automatically Sign up to receive the latest news and ratings for LAB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LAB vs. The Competition Export to ExcelMetricStandard BioToolsMEDICAL INFO SYS IndustryMedical SectorNASDAQ ExchangeMarket Cap$504.23M$2.28B$6.10B$10.52BDividend YieldN/AN/A5.51%4.70%P/E RatioN/A37.1985.6826.85Price / Sales2.8512.27585.01185.67Price / CashN/A60.2026.3031.10Price / Book1.0212.7713.256.72Net Income-$138.88M-$63.46M$3.30B$276.44M7 Day PerformanceN/A4.72%4.70%3.13%1 Month PerformanceN/A7.17%8.43%10.21%1 Year Performance-28.57%41.21%88.01%40.35% Standard BioTools Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LABStandard BioTools2.6063 of 5 stars$1.30-1.5%$1.55+19.2%-28.6%$504.23M$174.43M0.00620TXG10x Genomics4.2602 of 5 stars$11.34-3.2%$13.65+20.4%-36.9%$1.46B$610.78M-16.201,240High Trading VolumeEYPTEyepoint Pharmaceuticals1.6491 of 5 stars$14.05+1.1%$26.86+91.2%+57.8%$958.09M$51.90M-5.24120Positive NewsAEHRAehr Test Systems1.6702 of 5 stars$30.45+0.9%N/A+158.2%$904.76M$58.97M-234.2190Trending NewsAnalyst ForecastGap DownALNTAllient2.5849 of 5 stars$43.28-1.2%$35.00-19.1%+140.9%$742.28M$519.60M50.332,525Positive NewsTRNSTranscat3.4354 of 5 stars$72.73-1.3%$112.20+54.3%-39.4%$686.82M$278.42M50.861,245CTKBCytek Biosciences2.0205 of 5 stars$3.38-0.6%$5.60+65.7%-20.6%$432.56M$200.45M-67.60500Positive NewsSENSSenseonics2.3944 of 5 stars$0.44-3.8%$1.54+247.5%+64.7%$360.50M$25.47M-3.4090News CoverageGap DownQSIQuantum-Si2.5132 of 5 stars$1.39-6.7%$3.48+150.0%+105.7%$301.72M$3.06M-2.04150Gap DownFEIMFrequency Electronics2.7463 of 5 stars$32.09+6.6%$43.00+34.0%+217.3%$293.55M$69.81M14.01200MASS908 Devices1.6912 of 5 stars$8.15+1.7%$8.00-1.8%+150.3%$287.25M$59.63M-15.0960News CoveragePositive News Related Companies and Tools Related Companies 10x Genomics Alternatives Eyepoint Pharmaceuticals Alternatives Aehr Test Systems Alternatives Allient Alternatives Transcat Alternatives Cytek Biosciences Alternatives Senseonics Alternatives Quantum-Si Alternatives Frequency Electronics Alternatives 908 Devices Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LAB) was last updated on 10/7/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Standard BioTools Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Standard BioTools With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
